{"id":"NCT00322231","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)","officialTitle":"A Phase III Clinical Trial to Study the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live in Subjects With a History of Herpes Zoster","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2007-07","completion":"2007-07","firstPosted":"2006-05-05","resultsPosted":"2010-12-15","lastUpdate":"2015-01-26"},"enrollment":101,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"zoster vaccine live (ZOSTAVAX™)","otherNames":["Zostavax"]},{"type":"BIOLOGICAL","name":"Comparator: Placebo","otherNames":[]}],"arms":[{"label":"ZOSTAVAX™ / Placebo","type":"EXPERIMENTAL"},{"label":"Placebo / ZOSTAVAX™","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether the investigational zoster vaccine, is generally well tolerated when administered to participants with a history of herpes zoster.","primaryOutcome":{"measure":"Vaccine-related Serious Adverse Experiences (SAEs) for 28 Days Postvaccination","timeFrame":"To Day 28 postvaccination","effectByArm":[{"arm":"ZOSTAVAX™","deltaMin":0,"sd":null},{"arm":"Placebo","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20416263"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":98},"commonTop":["Injection Site Pain","Injection Site Erythema","Injection Site Swelling","Injection Site Pruritus"]}}